Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | PEPD | P12955 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3482455 | 0.82 | KIF11 (0.53) | ALDH1A1P2RX1MAPTKIF11LMNA | |
| SCHEMBL1787750 | 0.82 | PEPD (0.56) | ALDH1A1PEPDNPC1HSD17B10GAA | |
| SCHEMBL30543026 | 0.81 | GPR35 (0.50) | ALDH1A1 | |
| SCHEMBL13863227 | 0.81 | ALDH1A1 (0.47) | ALDH1A1PEPDHSD17B10GAAMAPT | |
| SCHEMBL27193043 | 0.80 | RAB9A (0.50) | NPC1EGFRP2RX1P2RX4P2RX7 | |
| SCHEMBL4109329 | 0.80 | ALDH1A1 (0.41) | ALDH1A1NPC1EGFRP2RX1P2RX4 | |
| SCHEMBL6073193 | 0.79 | ALDH1A1 (0.54) | ALDH1A1PEPDNPC1EGFRHSD17B10 | |
| SCHEMBL7142754 | 0.79 | MEN1 (0.52) | ALDH1A1EGFRP2RX1P2RX4P2RX7 | |
| SCHEMBL167713 | 0.79 | MEN1 (0.67) | ALDH1A1NPC1GAAMAPTMEN1 | |
| SCHEMBL30104928 | 0.78 | ALDH1A1 (0.49) | ALDH1A1NPC1HSD17B10GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111526877-B | Compounds and compositions for IRE1 inhibition | 奥普提卡拉公司 | 2023-08-25 | — | — | CN | claimed |
| JP-2007511596-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1687309-A1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL IN TREATMENT OF CANCER | Pfizer Products Inc. (US) | 2006-08-09 | — | — | EP | claimed |
| EP-1578751-A1 | PYRROLOPYRIMIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| WO-2005047289-A1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL IN TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2005-05-26 | — | — | WO | claimed |
| WO-2004056830-A1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| EP-4744664-A2 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2024-11-21 | — | — | US | disclosed |
| US-RE50050-E1 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230366033-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-16 | — | — | US | disclosed |
| CN-111526877-B | Compounds and compositions for IRE1 inhibition | 奥普提卡拉公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-109384729-B | Pyrimidinedione compounds for cardiac disorders | 迈奥卡迪亚公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2009013444-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008109238-A1 | SUBSTITUTED CYCLOPENTYL PIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2007129060-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| EP-1578751-A1 | PYRROLOPYRIMIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004056830-A1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| EP-1062207-A1 | 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000037447-A1 | 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | ALDH1A1 1556/4885PEPD 1120/4885NPC1 2234/4885 |
| US-20230366033-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | GRB2, RAD51, MRE11 | ALDH1A1 3059/4885PEPD 3727/4885NPC1 4337/4885 |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | ALDH1A1 1556/4885PEPD 1120/4885NPC1 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.